Journal article
AβPP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer’s Disease
Journal of Alzheimer's disease, Vol.37(2), pp.343-355
2013
DOI: 10.3233/JAD-130578
PMCID: PMC3971881
PMID: 23948888
Abstract
A systematic approach was used to identify AβPP-selective BACE inhibitors (ASBI) and to evaluate their
in vivo
ability to modulate AβPP processing selectively. We identified a bioflavonoid nutritional supplement as a molecular lead that acts as an ASBI in cell models, and show that increasing brain levels of this bioflavonoid through a pro-drug approach leads to reduction of Aβ
42
in an Alzheimer’s disease mouse model. ASBIs represent a novel class of candidate therapeutic agents for Alzheimer’s disease.
Details
- Title: Subtitle
- AβPP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer’s Disease
- Creators
- Olivier Descamps - Buck Institute for Research on Aging, Novato, CA, USAPatricia Spilman - Buck Institute for Research on Aging, Novato, CA, USAQiang Zhang - Buck Institute for Research on Aging, Novato, CA, USAClare P Libeu - Buck Institute for Research on Aging, Novato, CA, USAKaren Poksay - Buck Institute for Research on Aging, Novato, CA, USAOlivia Gorostiza - Buck Institute for Research on Aging, Novato, CA, USAJesus Campagna - Buck Institute for Research on Aging, Novato, CA, USABarbara Jagodzinska - Buck Institute for Research on Aging, Novato, CA, USADale E Bredesen - Buck Institute for Research on Aging, Novato, CA, USAVarghese John - Buck Institute for Research on Aging, Novato, CA, USA
- Resource Type
- Journal article
- Publication Details
- Journal of Alzheimer's disease, Vol.37(2), pp.343-355
- DOI
- 10.3233/JAD-130578
- PMID
- 23948888
- PMCID
- PMC3971881
- NLM abbreviation
- J Alzheimers Dis
- ISSN
- 1387-2877
- eISSN
- 1875-8908
- Language
- English
- Date published
- 2013
- Academic Unit
- Neurology
- Record Identifier
- 9984013202702771
Metrics
28 Record Views